Mission
At ProNeurogen, we are deeply committed to improving the lives of patients with vascular dementia by developing new therapies with the potential to slow the progression of disease and help individuals maintain healthy brains for life.
Vision
To be the global leader in protecting brain health of millions by developing life-changing therapies to treat cognitive impairment associated with neurodegenerative diseases.
Leadership Team
Executive Team Members
Meredith hay, Ph.D
Tamara Crockett, Esq
President and Head of BD
Holly Sparkmen, CPA
Chief Financial Officer
Bruce Coull, MD
Chief Medical Officer
Jeremy Riley
Director of Operations
Chris Rhodes, Ph.D.
Lead, Peptide Formulations
Board of Directors
Meredith Hay, Ph.D.
Founder and Board Chair
Meredith is the visionary and one of the inventors of the founding technology. She has over 30 years of experience in neuroscience and cardiovascular neurophysiology. She is the former Executive Vice President and Chief Operating Officer for the University of Arizona for former Vice President for Research, University of Iowa. She currently is a tenured professor at the University of Arizona College of Medicine. Dr. Hay has generated over $50 M in external R&D funding and nearly 30 NIH and related grants.
Gillian Thackay, Esq
Previous Vice President & Chief IP Counsel, ThermoFisher Scientific
ProNeurogen Director
Berkeley, CA
Gillian is an award-winning lawyer who protects the rights of some of the world’s most high-tech innovators. Her multi-faceted approach integrates law, business, and practicality to help clients reach their goals. She is registered to practice at the USPTO, and admitted in California.
Tamara Crockett, Esq.
President and ProNeurogen Director
Tamara joined the board of directors in 2014. Tamara is an attorney with 25+ years experience in technology development, intellectual property, contract negotiation and commercialization of emerging technologies. She is licensed in the states of NY, MA, DC and AZ.
Elizabeth Hocking, Esq
ProNeurogen Director and Board Secretary
Retired, Argonne National Laboratory, USA and ProNeurogen Director
Washington, D.C.
Elizabeth joined the board of directors in 2015. Ms. Hocking has over 30 years of experience as a federal policy analyst and currently serves as ProNeurogen’s Board Secretary.
Scientific Advisory Board
Eric Reiman, M.D.
International leader in the area of developing new therapies to prevent and treat Alzheimer’s disease. CEO of Banner Research and Executive Director of the Banner Alzheimer’s institute in Phoenix, AZ International renowned clinical Has over 25 years experience in dementia and Alzheimer’s disease.
Constantino Iadecola, M.D.
Director and Chair of the Feil Family Brain and Mind Research Institute and the Anne Parrish Titzell Professor of Neurology at Weill Cornell Medicine.
A world leader in vascular dementia with nearly 30 years experience in neurology and neuroscience. Dr. Iadecola is the Director of the Brain and Mind Research Institute Weill Cornell Medical College and Professor of Neurology and Neuroscience, Weill Cornell Medical College.
Roberta Brinton, Ph.D.
Director, Center for Innovation in Brain Science, University of Arizona
Internationally recognized expert in the cause and treatment of Alzheimer’s disease. Her findings have re-shaped how the field understands the disease and unlocked the potential for new and innovative therapies to prevent and treat Alzheimer’s.
